Golden
Haya Therapeutics

Haya Therapeutics

A pre-clinical biopharmaceutical company that is utilizing data from RNA to treat heart failure. It was founded in 2019 and is located in Lausanne, Switzerland. 

Haya Therapeutics is a Switzerland-based company that is researching RNA-therapeutics, specifically on long noncoding RNA.It is in the pre-clinical stages of its research and testing. It has the stated goal of being the first company to translate its research on long noncoding RNA to treat to heart failure. 

Product

The company is researching the RNA molecule that causes the scarring which leads to heart failure. It utilizes the knowledge of Wisper (Wisp2 super-enhancer-associated RNA) to treat the underlying causes of heart failure. It is developing a method to inject a modified DNA molecule that would affect the Wisper. Haya Therapeutics is testing its research on animals with the stated intention of eventually testing and treating humans. As of 2019, the test results have been successful in preventing the development of heart failure in animal testing.



Funding

The company is funded by several investors, such as Venture Kick and Start Lab.It has had four funding rounds: two grants, one seed, and one debt financing round. 





Timeline

People

Name
Role
LinkedIn

Daniel Blessing, PhD

CTO and Co-Founder



Samir Ounzain, PhD

CEO and Co-Founder



Thierry Pedrazzini, PhD

Chair of the Scientific Advisory Board

& Co-Founder



Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

HAYA Therapeutics 2019 Venture winner

July 8, 2019

Companies

Company
CEO
Location
Products/Services









References